Nature Reviews Cardiology, Published online: 16 September 2026; doi:10.1038/s41569-026-01353-0Data from the ACACIA-HCM trial show that treatment with the myosin inhibitor aficamten improves exercise capacity and patient-reported health status compared with placebo in patients with non-obstructive hypertrophic cardiomyopathy.

Nature Reviews Cardiology, Published online: 15 September 2026; doi:10.1038/s41569-026-01352-1Zila-Velasque discusses the initial studies linking high-altitude hypoxia to the risk of congenital heart defects.

Nature Reviews Cardiology, Published online: 08 September 2026; doi:10.1038/s41569-026-01349-wTobias Lerchner and Stephane Heymans discuss the study that provided seminal evidence linking genetic variation to susceptibility to acute myocarditis.

Nature Reviews Cardiology, Published online: 02 September 2026; doi:10.1038/s41569-026-01346-zIn this Tools of the Trade, Ackers-Johnson and Pavlovic describe a Langendorff-free approach to isolate cardiomyocytes without the technical hurdles associated with the conventional Langendorff perfusion procedure.

Nature Reviews Clinical Oncology, Published online: 17 September 2026; doi:10.1038/s41571-026-01206-2A new chimeric antigen receptor (CAR) T cell product consists of autologous T cells expressing an affinity-tuned glypican 3-targeted CAR and armoured to secrete a dominant-negative TGFβ receptor II. This cell product was tested in 36 patients with hepatocellular carcinoma and, although the initial efficacy results were promising, antigen loss and limited progression-free survival remain concerns. Here we discuss what else is needed to bring CAR T cells for solid tumours into the clinic.

Nature Reviews Clinical Oncology, Published online: 11 September 2026; doi:10.1038/s41571-026-01205-3Publisher Correction: Beyond cold to hot: oncolytic virotherapy as the next cornerstone of immuno-oncology

Nature Reviews Clinical Oncology, Published online: 03 September 2026; doi:10.1038/s41571-026-01198-zThe development of diverse immunotherapeutic modalities has revolutionized the treatment of cancer but the effectiveness of these therapies remains restricted by fundamental mechanistic limitations relating to the generation of tumour-specific T cells, and their activation and/or access into the tumour microenvironment. In this Perspective, the authors position oncolytic viruses as a foundational immuno-oncology platform for systemic immune reprogramming to simultaneously overcome these availability, activation and admission barriers, and delineate four pillars for the development of a new generation of oncolytic virotherapies.

Nature Reviews Clinical Oncology, Published online: 26 August 2026; doi:10.1038/s41571-026-01199-yThe global cancer burden is projected to rise substantially in the coming decades, driven largely by population growth and ageing. Yet cancer patterns and outcomes vary widely across regions, reflecting differences in exposures, healthcare capacity and access to care. Translating these evolving epidemiological patterns into effective and equitable cancer-control strategies is increasingly urgent.